MX2010008696A - Composiciones de proteina estabilizadas. - Google Patents

Composiciones de proteina estabilizadas.

Info

Publication number
MX2010008696A
MX2010008696A MX2010008696A MX2010008696A MX2010008696A MX 2010008696 A MX2010008696 A MX 2010008696A MX 2010008696 A MX2010008696 A MX 2010008696A MX 2010008696 A MX2010008696 A MX 2010008696A MX 2010008696 A MX2010008696 A MX 2010008696A
Authority
MX
Mexico
Prior art keywords
protein compositions
stabilized protein
specific binding
binding agents
compositions
Prior art date
Application number
MX2010008696A
Other languages
English (en)
Inventor
Margaret Ricci
Roberta Bonk
Mingda Eu
Amy Huinker
Monica Pallitto
Nicole Stackhouse
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2010008696A publication Critical patent/MX2010008696A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Abstract

Se proporcionan composiciones estabilizadas de agentes de unión específicos para RANKL, agentes de unión específicos para TNF y/o agentes de unión específicos para IL-1R1 en recipientes. También se proporcionan métodos de elaboración y uso de las composiciones.
MX2010008696A 2008-02-07 2009-02-05 Composiciones de proteina estabilizadas. MX2010008696A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6506508P 2008-02-07 2008-02-07
PCT/US2009/000759 WO2009099641A2 (en) 2008-02-07 2009-02-05 Stabilized protein compositions

Publications (1)

Publication Number Publication Date
MX2010008696A true MX2010008696A (es) 2010-08-30

Family

ID=40532483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008696A MX2010008696A (es) 2008-02-07 2009-02-05 Composiciones de proteina estabilizadas.

Country Status (14)

Country Link
US (1) US20110060290A1 (es)
EP (1) EP2249801A2 (es)
JP (2) JP2011519347A (es)
KR (1) KR20100138908A (es)
CN (2) CN103720587A (es)
AU (1) AU2009210741A1 (es)
BR (1) BRPI0908361A2 (es)
CA (1) CA2714006A1 (es)
EA (1) EA201001223A1 (es)
IL (1) IL207340A0 (es)
MX (1) MX2010008696A (es)
SG (1) SG10201402265YA (es)
WO (1) WO2009099641A2 (es)
ZA (2) ZA201005779B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
WO2014011672A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
WO2015006444A1 (en) * 2013-07-10 2015-01-15 Merit Medical Systems, Inc. Pre-loaded syringes and methods related thereto
EP3828202A1 (en) * 2014-05-12 2021-06-02 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
EP3191576A4 (en) * 2014-09-12 2018-04-18 Anthrogenesis Corporation Methods for quantifying particulates in cell culture
EP3202389A4 (en) * 2014-10-02 2018-06-20 Terumo Kabushiki Kaisha Medical container for accommodating protein solution preparation therein
CN107148287A (zh) 2014-10-30 2017-09-08 豪夫迈·罗氏有限公司 注射器和注射器的制备方法
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
KR20180083377A (ko) * 2015-11-18 2018-07-20 포르미콘 아게 Vegf 안타고니스트를 함유하는 사전충전형 플라스틱 주사기
MX2018006092A (es) 2015-11-18 2019-01-31 Formycon Ag Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
KR20180105123A (ko) 2015-11-18 2018-09-27 에스아이오2 메디컬 프로덕츠, 인크. 안과 제제용 제약 패키지
WO2017184880A1 (en) * 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
EP3449963B1 (en) * 2016-04-25 2023-09-27 Terumo Kabushiki Kaisha Syringe barrel for pre-filled syringe, syringe system, and pre-filled syringe
WO2018049184A1 (en) * 2016-09-09 2018-03-15 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
EP3528787A4 (en) 2016-10-21 2020-05-06 Amgen Inc. PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION
EP3370040B1 (de) 2017-03-02 2021-04-21 Fresenius Kabi Austria GmbH Verfahren zur bestimmung eines gasvolumens einer fertigspritze und verwendung des verfahrens zur eichung einer anlage zum abfüllen einer fertigspritze
JOP20190255A1 (ar) * 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
KR20200003107A (ko) 2017-05-02 2020-01-08 머크 샤프 앤드 돔 코포레이션 항-lag3 항체의 제제, 및 항-lag3 항체 및 항-pd-1 항체의 공동-제제
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US20200171244A1 (en) 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
EP3775315A1 (en) 2018-03-27 2021-02-17 SiO2 Medical Products, Inc. Vessels, containers, and surfaces coated with water barrier coatings
JP2019048091A (ja) * 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
SG11202104702VA (en) * 2018-11-14 2021-06-29 Avm Biotechnology Llc Stable glucocorticoid formulation
KR20210079373A (ko) * 2018-11-16 2021-06-29 삼성바이오에피스 주식회사 단백질을 포함하는 안정한 액상 조성물
CN109821076B (zh) * 2019-03-13 2021-05-07 陕西师范大学 一种抗凝抗感染的多功能涂层的制备方法及抗凝抗感染的多功能材料
HUE057779T2 (hu) * 2019-03-29 2022-06-28 Kortuc Inc Hidrogén-peroxid oldattal elõtöltött fecskendõ, amelynek kiváló hidrogén-peroxid eltarthatósága van szilikonolaj alapján (olaj kompozíció, amely tartalmazza az említett szilikonolajat)
JPWO2021153511A1 (es) * 2020-01-28 2021-08-05
CA3192661A1 (en) 2020-09-18 2022-03-24 Yuri Ikawa Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease
EP4313211A1 (en) * 2021-03-30 2024-02-07 SCHOTT Pharma Schweiz AG System for low-temperature storage of a pharmaceutical composition, liquid composition, method and uses
WO2022254007A1 (en) * 2021-06-03 2022-12-08 Becton Dickinson France Method of making a low-silicone oil system for a medical injection device
TW202323810A (zh) * 2021-10-08 2023-06-16 日商中外製藥股份有限公司 預填充式注射器製劑的調製方法
JP7220335B1 (ja) * 2021-10-08 2023-02-09 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体の製剤
WO2024049793A1 (en) * 2022-08-30 2024-03-07 Amgen Inc. System and method of limiting subvisible particles in a syringe

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652763A (en) * 1985-03-29 1987-03-24 Energy Sciences, Inc. Electron-beam irradiation sterilization process
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6551576B1 (en) * 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5519984A (en) * 1995-03-16 1996-05-28 Mallinckrodt Medical, Inc. Methods for packaging a pressure or vacuum sensitive product
JP3329219B2 (ja) * 1997-02-05 2002-09-30 スズキ株式会社 船外機の電装部品設置構造
CA2306206A1 (en) * 1997-10-15 1999-04-22 Masaki Yui Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution
US6274169B1 (en) * 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
ATE389414T1 (de) * 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
US6595961B2 (en) * 2001-04-16 2003-07-22 Becton, Dickinson And Company Sterilizable transfer or storage device for medicaments, drugs and vaccines
DE122010000047I1 (de) * 2001-06-26 2011-05-05 Amgen Fremont Inc Antikörper gegen opgl
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20030180287A1 (en) * 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
MXPA05012476A (es) * 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Estabilizacion de proteina en solucion.
RU2006101216A (ru) * 2003-08-01 2007-07-20 Амген Инк. (US) Кристаллические полипептиды 2 фактора некроза опухолей

Also Published As

Publication number Publication date
ZA201109364B (en) 2015-11-25
WO2009099641A3 (en) 2011-02-24
JP2011519347A (ja) 2011-07-07
IL207340A0 (en) 2010-12-30
EA201001223A1 (ru) 2011-06-30
AU2009210741A1 (en) 2009-08-13
WO2009099641A2 (en) 2009-08-13
SG10201402265YA (en) 2014-08-28
JP2015042638A (ja) 2015-03-05
US20110060290A1 (en) 2011-03-10
BRPI0908361A2 (pt) 2015-04-07
KR20100138908A (ko) 2010-12-31
CA2714006A1 (en) 2009-08-13
EP2249801A2 (en) 2010-11-17
CN103720587A (zh) 2014-04-16
CN102202643A (zh) 2011-09-28
ZA201005779B (en) 2014-12-23

Similar Documents

Publication Publication Date Title
MX2010008696A (es) Composiciones de proteina estabilizadas.
MX345226B (es) Formulaciones de moleculas de union a antigeno de dominio sencillo.
GB201020995D0 (en) Biological materials and uses thereof
PH12015500806A1 (en) Binding molecules to the human ox40 receptor
MY162737A (en) 4-1bb binding molecules
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2009111508A3 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2009111450A3 (en) Metalloproteinase 9 binding proteins
TN2011000283A1 (en) Human cgrp receptor binding proteins
PH12013501799A1 (en) Compositions and methods comprising cellulase variants with reduced affinity to non-cellulosic materials
TW200637490A (en) Fertilizer-compatible composition
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MX2010008874A (es) Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
WO2011028883A3 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2008021250A3 (en) Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
MX2010001723A (es) Formulaciones de anticuerpos y moleculas de fusion-fc usando policationes.
IN2012DN05145A (es)
IN2012DN01493A (es)
WO2010096754A8 (en) Compositions and methods to prevent and/or treat cancer with pa -card

Legal Events

Date Code Title Description
FA Abandonment or withdrawal